11th Jan 2021 17:27
Verici Dx PLC - clinical diagnostics developer for organ transplant - Expands scope of licence agreement with Mount Sinai's Icahn School of Medicine. The expanded scope includes additional patent filing relating to gene expression in a blood-based test to predict fibrosis and graft rejection risk. Interstitial fibrosis and tubular atrophy is a significant complication in between 50% and 65% of transplants at 12 to 24 months and it a major graft rejection cause in the first year following transplantation.
The company said development of a product able to fibrosis and rejection risk using Verici's core technological approach would extend the Verici Dx portfolio and complements Verici's existing flagship Clarava and Tuteva diagnostic assays. Clarava is a pre-transplant test for the risk of early acute rejection while Tuteva is a post-transplant diagnosis focusing on acute cellular rejection.
Chief Executive Sara Barrington: "The development of a product that can predict the risk of long-term graft failure, alongside our flagship products Clarava and Tuteva, would establish an end-to-end solution for clinicians seeking to understand how a patient will and is responding to organ transplant. There is a critical need for more personalised diagnostic information within transplant care, and in particular technologies informing earlier interventions with anti-fibrotic therapies in advance of irreversible organ damage."
Current stock price: 64.00 pence; up 8.5% on Monday
Year-to-date change: up 9.4%
By Anna Farley; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Verici Dx